|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Xenograft model was established to investigate the function of <i>miR-802</i> in carcinogenesis <i>in vivo</i> The direct regulation of Flotillin-2 (Flot2) by <i>miR-802</i> was identified using luciferase reporter assay.
|
28188157 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When SB2-flot-2 cells were compared with SB2-vector-control cells on a cancer gene pathway array, SB2-flot-2 cells had increased expression of protease activated receptor 1 (PAR-1) mRNA, a transmembrane, G-protein-coupled receptor involved in melanoma progression.
|
15492257 |
2004 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
When SB2-flot-2 cells were compared with SB2-vector-control cells on a cancer gene pathway array, SB2-flot-2 cells had increased expression of protease activated receptor 1 (PAR-1) mRNA, a transmembrane, G-protein-coupled receptor involved in melanoma progression.
|
15492257 |
2004 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified <i>miR-802</i> as a novel tumor suppressor in PCa progression and elucidated a novel mechanism of the <i>miR-802</i>/Flot2 axis in the regulation of EMT, which may be a potential therapeutic target.
|
28188157 |
2017 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified <i>miR-802</i> as a novel tumor suppressor in PCa progression and elucidated a novel mechanism of the <i>miR-802</i>/Flot2 axis in the regulation of EMT, which may be a potential therapeutic target.
|
28188157 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified <i>miR-802</i> as a novel tumor suppressor in PCa progression and elucidated a novel mechanism of the <i>miR-802</i>/Flot2 axis in the regulation of EMT, which may be a potential therapeutic target.
|
28188157 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also isolated cancer stem-like cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found that this cell population has significantly higher tumor-initiating ability to generate DCIS compared with the non-stem-like population.
|
23208501 |
2013 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We also isolated cancer stem-like cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found that this cell population has significantly higher tumor-initiating ability to generate DCIS compared with the non-stem-like population.
|
23208501 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also isolated cancer stem-like cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found that this cell population has significantly higher tumor-initiating ability to generate DCIS compared with the non-stem-like population.
|
23208501 |
2013 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
We also isolated cancer stem-like cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found that this cell population has significantly higher tumor-initiating ability to generate DCIS compared with the non-stem-like population.
|
23208501 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using QRT-PCR data we identified a four-gene model (PSMD10, HSD17B12, FLOT2 and KRT17) that predicts M/NM status with 77% success in a separate 79-sample validation group of HNSCC samples.
|
18679425 |
2008 |
|
Solid Neoplasm
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Up-regulation of Flot-2 protein is related to lymph node metastasis and poor prognosis in human solid tumors.
|
27981826 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Univariate and multivariate analyses indicated that high FLOT2 expression was an independent poor prognostic factor for NSCLC patients.
|
25755751 |
2015 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between the human flotillin-2 gene polymorphism and CAD in the Chinese Han population.
|
26556629 |
2015 |
|
Mammary Tumorigenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To examine the role of Flot2 in mammary tumorigenesis and lung metastasis, we used an in vivo molecular genetics approach, crossing a well-characterized transgenic mouse model of breast cancer, the MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mouse, with gene-targeted Flot2(-/-) mice.
|
23146906 |
2013 |
|
Tumor Progression
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Thus, Flot-2 exerts a pro-neoplastic role in NPC and is involved in tumor progression and metastasis.
|
26206082 |
2015 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
These were validated offline in their ability to identify the ESA targeted with a study-defined ablation response (AF termination or cycle length [CL] slowing of ≥30 ms).
|
31552697 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The subpopulation of human colorectal tumor cells with an ESA(+)CD44(+) phenotype are uniquely responsible for tumorigenesis and have the capacity to generate heterogeneous tumors in a xenograft setting (i.e.CoCSC).
|
18560594 |
2008 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The subpopulation of human colorectal tumor cells with an ESA(+)CD44(+) phenotype are uniquely responsible for tumorigenesis and have the capacity to generate heterogeneous tumors in a xenograft setting (i.e.CoCSC).
|
18560594 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicated that: (1) elevated flotillins predicted poorer OS (overall survival) (HR = 2.17, 95% CI 1.87 to 2.52; HR = 1.61, 95% CI 1.44 to 1.81) and DFS (disease-free survival) (HR = 2.41, 95% CI 1.83 to 3.18; HR = 3.01, 95% CI 2.12 to 4.27) in patients with cancer; (2) Subgroup analysis showed that the prognostic value of flotillin-1 on OS and DFS in the investigated tumors were not altered by tumor type (such as digestive system cancers, renal cell cancer, lung cancer, or others), country (China or Canada), cutoff value, detection method, analysis type or paper quality and flotillin-2 overexpression indicates poor OS in human cancers except for nasopharyngeal carcinoma.
|
29499201 |
2018 |
|
Nasopharyngeal carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The results indicated that: (1) elevated flotillins predicted poorer OS (overall survival) (HR = 2.17, 95% CI 1.87 to 2.52; HR = 1.61, 95% CI 1.44 to 1.81) and DFS (disease-free survival) (HR = 2.41, 95% CI 1.83 to 3.18; HR = 3.01, 95% CI 2.12 to 4.27) in patients with cancer; (2) Subgroup analysis showed that the prognostic value of flotillin-1 on OS and DFS in the investigated tumors were not altered by tumor type (such as digestive system cancers, renal cell cancer, lung cancer, or others), country (China or Canada), cutoff value, detection method, analysis type or paper quality and flotillin-2 overexpression indicates poor OS in human cancers except for nasopharyngeal carcinoma.
|
29499201 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results indicated that: (1) elevated flotillins predicted poorer OS (overall survival) (HR = 2.17, 95% CI 1.87 to 2.52; HR = 1.61, 95% CI 1.44 to 1.81) and DFS (disease-free survival) (HR = 2.41, 95% CI 1.83 to 3.18; HR = 3.01, 95% CI 2.12 to 4.27) in patients with cancer; (2) Subgroup analysis showed that the prognostic value of flotillin-1 on OS and DFS in the investigated tumors were not altered by tumor type (such as digestive system cancers, renal cell cancer, lung cancer, or others), country (China or Canada), cutoff value, detection method, analysis type or paper quality and flotillin-2 overexpression indicates poor OS in human cancers except for nasopharyngeal carcinoma.
|
29499201 |
2018 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The results indicated that: (1) elevated flotillins predicted poorer OS (overall survival) (HR = 2.17, 95% CI 1.87 to 2.52; HR = 1.61, 95% CI 1.44 to 1.81) and DFS (disease-free survival) (HR = 2.41, 95% CI 1.83 to 3.18; HR = 3.01, 95% CI 2.12 to 4.27) in patients with cancer; (2) Subgroup analysis showed that the prognostic value of flotillin-1 on OS and DFS in the investigated tumors were not altered by tumor type (such as digestive system cancers, renal cell cancer, lung cancer, or others), country (China or Canada), cutoff value, detection method, analysis type or paper quality and flotillin-2 overexpression indicates poor OS in human cancers except for nasopharyngeal carcinoma.
|
29499201 |
2018 |
|
Nasopharyngeal carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that PLCD3 may be an oncogenic protein in NPC and that it plays an important role in the progression of NPC partially by interacting with Flot2.
|
29115528 |
2018 |
|
Chronic Kidney Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
The objective of the study was to examine overall anemia management trends in non-dialysis patients with chronic kidney disease (CKD) from 2006 to 2015, and to evaluate the impact of Trial to Reduced Cardiovascular Events with Ananesp Therapy (TREAT)'s study results (October 2009) and the US Food and Drug Administration (FDA)'s (June 2011) safety warnings and guidelines on the use of ESA therapy in the current treatment of anemia.
|
30413150 |
2018 |